Breaking News, Collaborations & Alliances

Synthetic Bio, Fujifilm in CTM Alliance

Fujifilm Diosynth to make SYN-004 for trials targeting C. diff infectio

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Synthetic Biologics and partner Fujifilm Diosynth Biotechnologies have completed the protein expression evaluation of Synthetic Biologics’ oral beta-lactamase enzyme (SYN-004) targeting Clostridium difficile infections. Fujifilm analyzed and demonstrated a greater than 20-fold improvement in SYN-004 expression titers using its pAVEway platform (an E. coli system) compared to the Bacillus platform previously used. Fujifilm will manufacture SYN-004 material to support Synthetic Biologics’ pl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters